CoChat

Enhancing preclinical drug discovery with artificial intelligence

Open access
Vijayan, R.S.K., Kihlberg, Jan, Cross, Jason B., Poongavanam, Vasanthanathan · 2022 · Drug Discovery Today
Cited by 180

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

Artificial intelligence (AI) is becoming an integral part of drug discovery. It has the potential to deliver across the drug discovery and development value chain, starting from target identification and reaching through clinical development. In this review, we provide an overview of current AI technologies and a glimpse of how AI is reimagining preclinical drug discovery by highlighting examples where AI has made a real impact. Considering the excitement and hyperbole surrounding AI in drug discovery, we aim to present a realistic view by discussing both opportunities and challenges in adopting AI in drug discovery.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.drudis.2021.11.023

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Research works printed but not linked: 100

  1. Wouters, 2020, Research and development costs of new drugs–reply, JAMA, 324, 518, 10.1001/jama.2020.8651 · DOI
  2. Mullard, 2021, 2020 FDA drug approvals, Nat Rev Drug Discov, 20, 85, 10.1038/d41573-021-00002-0 · DOI
  3. Brown, 2021, A decade of FDA-approved drugs (2010–2019): trends and future directions, J Med Chem, 64, 2312, 10.1021/acs.jmedchem.0c01516 · DOI · Paper page
  4. Schuhmacher, 2021, Big techs and startups in pharmaceutical R&D - a 2020 perspective on artificial intelligence, Drug Discov Today, 26, 2226, 10.1016/j.drudis.2021.04.028 · DOI
  5. Aoyama, 1990, Neural networks applied to pharmaceutical problems. III. Neural networks applied to quantitative structure-activity relationship (QSAR) analysis, J Med Chem, 33, 2583, 10.1021/jm00171a037 · DOI · Paper page
  6. Klingler, 1988, Expert systems in the pharmaceutical industry, Drug Info J, 22, 249, 10.1177/009286158802200217 · doi:10.1177/009286158802200217
  7. Plenge, 2016, Disciplined approach to drug discovery and early development, Sci Transl Med, 8, 349PS315, 10.1126/scitranslmed.aaf2608 · DOI · Paper page
  8. De Cesco, 2020, TargetDB: a target information aggregation tool and tractability predictor, PLoS ONE, 15, 10.1371/journal.pone.0232644 · DOI
  9. Vignaux, 2020, Machine learning for discovery of gsk3beta inhibitors, ACS Omega, 5, 26551, 10.1021/acsomega.0c03302 · DOI · Paper page
  10. McCloskey, 2020, Machine learning on DNA-encoded libraries: a new paradigm for hit finding, J Med Chem, 63, 8857, 10.1021/acs.jmedchem.0c00452 · DOI · Paper page
  11. Stork, 2019, Hit dexter 2.0: Machine-learning models for the prediction of frequent hitters, J Chem Inf Model, 59, 1030, 10.1021/acs.jcim.8b00677 · DOI · Paper page
  12. Graff, 2021, Accelerating high-throughput virtual screening through molecular pool-based active learning, Chem Sci, 12, 7866, 10.1039/D0SC06805E · DOI · Paper page
  13. Yang, 2021, Efficient exploration of chemical space with docking and deep-learning, J Chem Theory Comput, 17, 7106, 10.1021/acs.jctc.1c00810 · DOI · Paper page
  14. Segall, 2012, Multi-parameter optimization: identifying high quality compounds with a balance of properties, Curr Pharm Des, 18, 1292, 10.2174/138161212799436430 · DOI · Paper page
  15. Hann, 2012, Finding the sweet spot: the role of nature and nurture in medicinal chemistry, Nat Rev Drug Discov, 11, 355, 10.1038/nrd3701 · DOI · Paper page
  16. Bian, 2021, Generative chemistry: drug discovery with deep learning generative models, J Mol Model, 27, 71, 10.1007/s00894-021-04674-8 · DOI · Paper page
  17. Webb, 2010, Continuous flow multi-step organic synthesis, Chem Sci, 1, 675, 10.1039/c0sc00381f · DOI · Paper page
  18. Irwin, 2021, Deep imputation on large-scale drug discovery data, Applied AI Letters, 2, 10.1002/ail2.31 · DOI
  19. Whitehead, 2019, Imputation of assay bioactivity data using deep learning, J Chem Info Model, 59, 1197, 10.1021/acs.jcim.8b00768 · DOI · Paper page
  20. Irwin, 2020, Practical applications of deep learning to impute heterogeneous drug discovery data, J Chem Inf Model, 60, 2848, 10.1021/acs.jcim.0c00443 · DOI · Paper page
  21. Dolgos, 2016, Translational medicine guide transforms drug development processes: the recent Merck experience, Drug Discov Today, 21, 517, 10.1016/j.drudis.2016.01.003 · DOI
  22. Jimenez, 1998, Supervised classification in high-dimensional space: geometrical, statistical, and asymptotical properties of multivariate data, IEEE Trans Syst Man Cybern, Part C (Applications and Reviews), 28, 39, 10.1109/5326.661089 · DOI · Paper page
  23. Popova, 2018, Deep reinforcement learning for de novo drug design, Sci Adv, 4, eaap7885, 10.1126/sciadv.aap7885 · DOI · Paper page
  24. Gomes, J, Ramsundar, B, Feinberg, E.N, Pande, V.S. Atomic convolutional networks for predicting protein–ligand binding affinity. arXiv 2017: arXiv:1703.10603 2017. · arXiv
  25. Gupta, 2018, Generative recurrent networks for de novo drug design, Mol Info, 37, 170011
  26. Sellwood, 2018, Artificial intelligence in drug discovery, Future Med Chem, 10, 2025, 10.4155/fmc-2018-0212 · DOI · Paper page
  27. Edfeldt, 2011, Fragment screening to predict druggability (ligandability) and lead discovery success, Drug Discov Today, 16, 284, 10.1016/j.drudis.2011.02.002 · DOI · Paper page
  28. Vukovic, 2018, Quantitative metrics for drug-target ligandability, Drug Discov Today, 23, 1258, 10.1016/j.drudis.2018.02.015 · DOI
  29. Berman, 2000, The Protein Data Bank, Nucleic Acids Res, 28, 235, 10.1093/nar/28.1.235 · DOI · Paper page
  30. Hillisch, 2004, Utility of homology models in the drug discovery process, Drug Discov Today, 9, 659, 10.1016/S1359-6446(04)03196-4 · DOI · Paper page
  31. Kinch, 2019, CASP 13 target classification into tertiary structure prediction categories, Proteins, 87, 1021, 10.1002/prot.25775 · DOI · Paper page
  32. Jumper, J, Evans, R, Pritzel, A, Green, T, Figurnov, M, Tunyasuvunakool, K. et al. (2020) High accuracy protein structure prediction using deep learning. In Fourteenth Critical Assessment of Techniques for Protein Structure Prediction. Davis: Protein Structure Prediction Center; 2020: 22–24.
  33. Andreeva, 2020, The scop database in 2020: expanded classification of representative family and superfamily domains of known protein structures, Nucleic Acids Res, 48, D376, 10.1093/nar/gkz1064 · DOI · Paper page
  34. Grant, 2004, Progress towards mapping the universe of protein folds, Genome Biol, 5, 107, 10.1186/gb-2004-5-5-107 · DOI
  35. Ehrt, 2016, Impact of binding site comparisons on medicinal chemistry and rational molecular design, J Med Chem, 59, 4121, 10.1021/acs.jmedchem.6b00078 · DOI · Paper page
  36. Simonovsky, 2020, DeeplyTough: learning structural comparison of protein binding sites, J Chem Inf Model, 60, 2356, 10.1021/acs.jcim.9b00554 · DOI · Paper page
  37. Zhu, 2013, Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis, J Med Chem, 56, 6560, 10.1021/jm301916b · DOI · Paper page
  38. Ripphausen, 2010, Quo vadis, virtual screening? A comprehensive survey of prospective applications, J Med Chem, 53, 8461, 10.1021/jm101020z · DOI · Paper page
  39. Damm-Ganamet, 2019, Accelerating lead identification by high throughput virtual screening: prospective case studies from the pharmaceutical industry, J Chem Inf Model, 59, 2046, 10.1021/acs.jcim.8b00941 · DOI
  40. Gorgulla, 2020, An open-source drug discovery platform enables ultra-large virtual screens, Nature, 580, 663, 10.1038/s41586-020-2117-z · DOI · Paper page
  41. Wang, 2017, PubChem bioassay: 2017 update, Nucleic Acids Res, 45, D955, 10.1093/nar/gkw1118 · DOI · Paper page
  42. Mendez, 2019, ChEMBL: towards direct deposition of bioassay data, Nucleic Acids Res, 47, D930, 10.1093/nar/gky1075 · DOI · Paper page
  43. Zhang, 2013, Discovery of novel antimalarial compounds enabled by QSAR-based virtual screening, J Chem Inf Model, 53, 475, 10.1021/ci300421n · DOI · Paper page
  44. Chen, 2020, Discovery of dual FGFR4 and EGFR inhibitors by machine learning and biological evaluation, J Chem Inf Model, 60, 4640, 10.1021/acs.jcim.0c00652 · DOI
  45. Donlin, 2021, Discovery of 5-nitro-6-thiocyanatopyrimidines as inhibitors of Cryptococcus neoformans and Cryptococcus gattii, ACS Med Chem Lett, 12, 774, 10.1021/acsmedchemlett.1c00038 · DOI
  46. Liu, 2021, Deep learning enables discovery of highly potent anti–osteoporosis natural products, Eur J Med Chem, 210, 10.1016/j.ejmech.2020.112982 · DOI
  47. Verkhivker, 2000, Deciphering common failures in molecular docking of ligand-protein complexes, J Comput Aided Mol Des, 14, 731, 10.1023/A:1008158231558 · DOI · Paper page
  48. Wicht, 2015, Bayesian models trained with HTS data for predicting beta-haematin inhibition and in vitro antimalarial activity, Bioorg Med Chem, 23, 5210, 10.1016/j.bmc.2014.12.020 · doi:10.1016/j.bmc.2014.12.020
  49. Yang, 2019, Machine learning models based on molecular fingerprints and an extreme gradient boosting method lead to the discovery of JAK2 inhibitors, J Chem Inf Model, 59, 5002, 10.1021/acs.jcim.9b00798 · DOI
  50. Liu, 2019, Deepscreening: a deep learning-based screening web server for accelerating drug discovery, Database (Oxford), 2019, baz104, 10.1093/database/baz104 · DOI
  51. Soufan, 2018, DPubChem: a web tool for qsar modeling and high-throughput virtual screening, Sci Rep, 8, 9110, 10.1038/s41598-018-27495-x · DOI
  52. Kitchen, 2004, Docking and scoring in virtual screening for drug discovery: methods and applications, Nat Rev Drug Discov, 3, 935, 10.1038/nrd1549 · DOI · Paper page
  53. Wallach, I, Dzamba, M, Heifets, A. AtomNet: a deep, convolutional neural network for bioactivity prediction in structure-based drug discovery. arXiv 2015: arXiv:1510.02855v1 · arXiv
  54. Gilson, 1997, The statistical-thermodynamic basis for computation of binding affinities: a critical review, Biophys J, 72, 1047, 10.1016/S0006-3495(97)78756-3 · DOI · Paper page
  55. Ashtawy, 2015, Machine-learning scoring functions for identifying native poses of ligands docked to known and novel proteins, BMC Bioinformatics, 16, S3, 10.1186/1471-2105-16-S6-S3 · DOI
  56. Bao, 2021, DeepBSP-a machine learning method for accurate prediction of protein-ligand docking structures, J Chem Inf Model, 61, 2231, 10.1021/acs.jcim.1c00334 · DOI
  57. Adeshina, 2020, Machine learning classification can reduce false positives in structure-based virtual screening, Proc Natl Acad Sci U S A, 117, 18477, 10.1073/pnas.2000585117 · DOI · Paper page
  58. Ballester, 2010, A machine learning approach to predicting protein-ligand binding affinity with applications to molecular docking, Bioinformatics, 26, 1169, 10.1093/bioinformatics/btq112 · DOI · Paper page
  59. Stepniewska-Dziubinska, 2018, Development and evaluation of a deep learning model for protein-ligand binding affinity prediction, Bioinformatics, 34, 3666, 10.1093/bioinformatics/bty374 · DOI · Paper page
  60. Zheng, 2019, Onionnet: A multiple-layer intermolecular-contact-based convolutional neural network for protein-ligand binding affinity prediction, ACS Omega, 4, 15956, 10.1021/acsomega.9b01997 · DOI · Paper page
  61. Durrant, 2011, NNScore 2.0: A neural-network receptor-ligand scoring function, J Chem Inf Model, 51, 2897, 10.1021/ci2003889 · DOI · Paper page
  62. Wang, 2017, Improving scoring-docking-screening powers of protein–ligand scoring functions using random forest, J Comput Chem, 38, 169, 10.1002/jcc.24667 · DOI · Paper page
  63. Shen, 2021, Can machine learning consistently improve the scoring power of classical scoring functions? Insights into the role of machine learning in scoring functions, Brief Bioinform, 22, 497, 10.1093/bib/bbz173 · DOI
  64. Benson, 2008, Binding MOAD, a high-quality protein-ligand database, Nucleic Acids Res, 36, D674, 10.1093/nar/gkm911 · DOI · Paper page
  65. Li, 2021, Machine-learning scoring functions for structure-based virtual screening, Wiley Interdiscip Rev Comput Mol Sci, 11, 10.1002/wcms.1478 · DOI · Paper page
  66. Sun, 2016, Constructing and validating high-performance miec–svm models in virtual screening for kinases: a better way for actives discovery, Sci Rep, 6, 24817, 10.1038/srep24817 · DOI
  67. Sieg, 2019, In need of bias control: evaluating chemical data for machine learning in structure-based virtual screening, J Chem Inf Model, 59, 947, 10.1021/acs.jcim.8b00712 · DOI · Paper page
  68. Clark, 2020, Virtual screening: Is bigger always better? Or can small be beautiful?, J Chem Info Model, 60, 4120, 10.1021/acs.jcim.0c00101 · DOI
  69. Darvas, 1974, Application of the sequential simplex method in designing drug analogs, J Med Chem, 17, 799, 10.1021/jm00254a004 · doi:10.1021/jm00254a004
  70. Bohm, 1992, Ludi: Rule-based automatic design of new substituents for enzyme inhibitor leads, J Comput Aided Mol Des, 6, 593, 10.1007/BF00126217 · DOI · Paper page
  71. Elbadawi, 2021, Advanced machine-learning techniques in drug discovery, Drug Discov Today, 26, 769, 10.1016/j.drudis.2020.12.003 · DOI · Paper page
  72. Meyers, 2021, De novo molecular design and generative models, Drug Discov Today, 26, 2707, 10.1016/j.drudis.2021.05.019 · DOI · Paper page
  73. Prykhodko, 2019, A de novo molecular generation method using latent vector based generative adversarial network, J Cheminform, 11, 74, 10.1186/s13321-019-0397-9 · DOI · Paper page
  74. Merk, 2018, Tuning artificial intelligence on the de novo design of natural-product-inspired retinoid x receptor modulators, Commun Chem, 1, 68, 10.1038/s42004-018-0068-1 · DOI · Paper page
  75. Zhavoronkov, 2020, Reply to ‘assessing the impact of generative ai on medicinal chemistry’, Nat Biotechnol, 38, 146, 10.1038/s41587-020-0417-3 · DOI
  76. Quentin, P, Olivier, M, Hamza, T, Adam, S, Anne, R, Arnaud, G. et al. Deep generative models for ligand-based de novo design applied to multi-parametric optimization. ChemRxiv. Published online January 25, 2021. http://dx.doi.org/10.26434/chemrxiv.13622417.v2. · doi:10.26434/chemrxiv.13622417.v2
  77. Young, 2011, Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity, Drug Discov Today, 16, 822, 10.1016/j.drudis.2011.06.001 · DOI · Paper page
  78. Martin, 2005, A bioavailability score, J Med Chem, 48, 3164, 10.1021/jm0492002 · DOI · Paper page
  79. van de Waterbeemd, 2003, ADMET in silico modelling: towards prediction paradise?, Nat Rev Drug Discov, 2, 192, 10.1038/nrd1032 · DOI · Paper page
  80. Lombardo, F, Desai, P.V, Arimoto, R, Desino, K.E, Fischer, H, Keefer, C.E. et al. In silico absorption, distribution, metabolism, excretion, and pharmacokinetics (ADME-PK): utility and best practices. An industry perspective from the international consortium for innovation through quality in pharmaceutical development. J Med Chem 2017; 60: 9097–9113. · DOI · Paper page
  81. Free, 1964, A mathematical contribution to structure-activity studies, J Med Chem, 7, 395, 10.1021/jm00334a001 · DOI · Paper page
  82. Sosnin, 2019, A survey of multi-task learning methods in chemoinformatics., Mol Inform, 38, 10.1002/minf.201800108 · DOI · Paper page
  83. Feinberg, 2020, Improvement in ADMET prediction with multitask deep featurization, J Med Chem, 63, 8835, 10.1021/acs.jmedchem.9b02187 · DOI · Paper page
  84. Wenzel, 2019, Predictive multitask deep neural network models for ADME-tox properties: learning from large data sets, J Chem Inf Model, 59, 1253, 10.1021/acs.jcim.8b00785 · DOI · Paper page
  85. Kenny, P.W, Sadowski, J. Structure modification in chemical databases. In: Oprea TI, ed. Chemoinformatics in Drug Discovery. Weinheim: Wiley–VHC Verlag GmbH & Co. KGaA; 2005: 271–285. · DOI · Paper page
  86. Kramer, 2018, Learning medicinal chemistry absorption, distribution, metabolism, excretion, and toxicity (ADMET) rules from cross-company matched molecular pairs analysis (MMPA), J Med Chem, 61, 3277, 10.1021/acs.jmedchem.7b00935 · DOI
  87. Corey, 1985, Computer-assisted analysis in organic synthesis, Science, 228, 408, 10.1126/science.3838594 · DOI · Paper page
  88. Corey, 1967, General methods for the construction of complex molecules, Pure Appl Chem, 14, 19, 10.1351/pac196714010019 · DOI · Paper page
  89. Plehiers, 2020, Artificial intelligence for computer-aided synthesis in flow: analysis and selection of reaction components, Front Chem Eng, 2, 5, 10.3389/fceng.2020.00005 · DOI
  90. Wang, 2021, Mapping the resources and approaches facilitating computer-aided synthesis planning, Org Chem Front, 8, 812, 10.1039/D0QO00946F · DOI
  91. Thakkar, 2021, Artificial intelligence and automation in computer aided synthesis planning, React Chem Eng, 6, 27, 10.1039/D0RE00340A · DOI · Paper page
  92. Dong, 2021, Deep learning in retrosynthesis planning: datasets, models and tools, Brief Bioinform, bbab391
  93. Struble, 2020, Current and future roles of artificial intelligence in medicinal chemistry synthesis, J Med Chem, 63, 8667, 10.1021/acs.jmedchem.9b02120 · DOI · Paper page
  94. Coley, 2017, Computer-assisted retrosynthesis based on molecular similarity, ACS Cent Sci., 3, 1237, 10.1021/acscentsci.7b00355 · DOI · Paper page
  95. Sacha, 2021, Molecule edit graph attention network: modeling chemical reactions as sequences of graph edits, J Chem Inf Model, 61, 3273, 10.1021/acs.jcim.1c00537 · DOI · Paper page
  96. Genheden, 2020, AiZynthFinder: a fast, robust and flexible open–source software for retrosynthetic planning, J Cheminform, 12, 70, 10.1186/s13321-020-00472-1 · DOI · Paper page
  97. Yan A. Ivanenkov, Y.A, Zhebrak, A, Bezrukov, D, Zagribelnyy, B, Aladinskiy, V, Polykovskiy, D, Putin, E, Kamya, P, Aliper, A, Zhavoronkov, A, Chemistry42: an AI-based platform for de novo molecular design. arXiv 2021: arXiv:2101.09050v1. · arXiv
  98. Klucznik, 2018, Efficient syntheses of diverse, medicinally relevant targets planned by computer and executed in the laboratory, Chem, 4, 522, 10.1016/j.chempr.2018.02.002 · DOI · Paper page
  99. Hu, 2012, Pfizer global virtual library (PGVL): a chemistry design tool powered by experimentally validated parallel synthesis information, ACS Comb Sci, 14, 579, 10.1021/co300096q · doi:10.1021/co300096q
  100. Mullard, 2017, The drug-maker’s guide to the galaxy, Nature, 549, 445, 10.1038/549445a · DOI

Cited by

See all 180

Metadata

Authors
Vijayan, R. S. K., Kihlberg, J., Cross, J. B., & Poongavanam, V.
Venue
Drug Discovery Today
Publisher
Elsevier BV
Published
2022-04
Volume
27
Issue
4
Pages
967-984
ISSN
1359-6446 (ISSN-L)
OpenAlex
W3217042593
Cited by
180
References
46
FWCI
11.25
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • Pfizer
  • Wayne State University

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Enhancing preclinical drug discovery with artificial intelligence. https://app.cochat.ai/papers/10.1016/j.drudis.2021.11.023
The paper
Vijayan, R. S. K., Kihlberg, J., Cross, J. B., & Poongavanam, V. (2022). Enhancing preclinical drug discovery with artificial intelligence. Drug Discovery Today. https://doi.org/10.1016/j.drudis.2021.11.023

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.